The results of a recent international study led by the University of Monash, Australian University, showed that a new cholesterol reduction medicine may be a more effective and easy way to protect people most at risk of heart attacks and strokes.
According to the study, a oral medicine is taken once a day known as Obysterapype, which shows through the clinical experiment that it significantly reduces both the low-density lipoprotein cholesterol, and the “LP-A” lipid protein “LP-A”, which are two main factors that contribute to cardiovascular disease.
Professor Stephen Nichols, director of the Victorian Heart Institute at the University of Monash and the leader of the study published in the New England Medical Journal, presented the results of the clinical experiment during the European Arterial Steel Society conference held in the Scottish city of Glasgow, highlighting that these results are important progress for patients who have difficulty in achieving the levels of targeted cholesterol using current treatments.
“We know that many people at risk of heart attacks or strokes do not decrease their cholesterol levels enough, even with the use of the best treatments currently available,” Nicole said.
Obeestepheep is a new promising option; The LDL cholesterol was not only reduced by more than 30%, but also recorded a decrease in the level of “LP-A”, which is difficult to control, and has been associated with an increase in the risk of heart disease, according to the study.
It is noteworthy that low -density sebaceous cholesterol, known as “harmful cholesterol”, accumulates in the blood vessels, which increases the risk of heart attacks and strokes.
As for the sebaceous protein (LP-A), it is a less well-known genetic risk factor, but it speeds up the arteries, and there are no widely approved treatments- so far- to reduce its levels, unlike (LDL).
In the experiment, which included 2500 participants suffering from chronic heart disease or a genetic rise in cholesterol, some of them were given “Octoterpel”, while others were given a fake treatment, as well as the usual cholesterol medications.
The researchers found that after 12 weeks, the average level of harmful cholesterol (LDL) decreased in patients who consumed “Obeestepheep” by 32.6%, and the level of LP-A decreased by 33.5%, and a large number of them achieved the recommended goals according to medical guidelines.